Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2021

01-10-2021

Monitoring the therapeutic effect of caplacizumab by von Willebrand Factor activity assays: Proceed with caution

Authors: Sean G. Yates, Dakota Deutsch, Ravi Sarode, Nicole De Simone

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Login to get access

Excerpt

In two randomized clinical trials, patients presenting with immune-mediated thrombotic thrombocytopenic purpura (iTTP) and treated with caplacizumab, a nanobody targeting von Willebrand factor (VWF), demonstrated accelerated platelet count recovery, required fewer therapeutic plasma exchange (PLEX) treatments, and showed a reduced length of stay [1, 2]. …
Literature
1.
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511–522CrossRef
2.
Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer JA et al (2020) Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost 18:479–484CrossRef
3.
Dutt T, Shaw RJ, Stubbs M, Yong J, Bailiff B, Cranfield T et al (2021) Real-world experience with caplacizumab in the management of acute TTP. Blood 137(13):1731–1740CrossRef
4.
Hollifield AL, Arnall JR, Moore DC (2020) Caplacizumab: an anti–von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Heal Pharm 77(15):1201–1207CrossRef
5.
Lker LAV, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L et al (2020) ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with iTTP. Blood Adv 4(13):3093–3101CrossRef
Metadata
Title
Monitoring the therapeutic effect of caplacizumab by von Willebrand Factor activity assays: Proceed with caution
Authors
Sean G. Yates
Dakota Deutsch
Ravi Sarode
Nicole De Simone
Publication date
01-10-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02492-6

Other articles of this Issue 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Go to the issue

OriginalPaper

Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients

OriginalPaper

COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography

OriginalPaper

Immature platelets in patients with Covid-19: association with disease severity

OriginalPaper

LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway

BriefCommunication

A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer

OriginalPaper

Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits